abstract |
The object of the present invention is the use of at least one cytoplasmic phospholipase A2 (cPLA2) in the manufacture of a medicament intended for preventive and / or curative symptomatic treatment of cystic fibrosis and in particular increased mucus secretion in cystic fibrosis It is. |